AIPG
AI Technology Group Inc.2.5000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.01MP/E (TTM)
-Basic EPS (TTM)
-0.15Dividend Yield
0%Recent Filings
8-K
Merger amendment extends timeline
AI Technology Group amended its merger agreement with AVM Biotechnology and Biomed 360 on January 27, 2026, confirming $2M in Tranche 1 and 2 convertible loans while scheduling three more $1M Tranche 2 installments through June 30, 2026, plus $10-25M Tranche 3 by closing. Closing extended to July 26, 2026, due to audit delays. Loans convert to shares at $1.00-$2.50, with 10% interest. Deadlines carry 30-day grace.
8-K
Name change to AVM Biotech
8-K
Merger funding extended
AI Technology Group extended funding dates for its exclusive proposed merger with AVM Biotechnology, targeting a 2026 close to fuel combined growth. AVM restarted its FDA Phase 2 OPAL Trial for AVM0703 in relapsed/refractory Non-Hodgkin's Lymphoma, planning 7-10 more patients after promising survival data in 30 subjects. Secured another $2M NCI grant, totaling $6.4M non-dilutive funding. Merger faces closing risks.
8-K
Acquires AVM via share swap
AI Technology Group completed its acquisition of AVM Biotechnology on December 15, 2025, issuing 100 common shares to sole shareholder Biomed 360 in exchange for all AVM shares, making AVM a wholly-owned subsidiary. AVM carries $1,125,000 in convertible debentures, set to convert into 584,800 Corporation shares. Deal targets tax-free reorganization status. Dilution looms from conversions.
10-Q
Q3 FY2025 results
AI Technology Group posted zero revenue for Q3 ended September 30, 2025, with operating expenses spiking to $29,628 from $750 y/y, driving net loss wider to $29,628 (derived). Nine-month net loss hit $33,889, up from $1,962 y/y, fueled by transfer agent fees, accounting, legal, consulting, and OTC costs per MD&A. Losses match operating levels exactly. Cash stayed at zero, propped by $20,644 related-party advances matching operating cash use; related-party debt climbed to $67,375. Change in control hit July 29, 2025, with new CEO taking 78.85% stake; proposed AVM acquisition advanced via October 7 share issuance of 27,958,695 to Biomed360 holders, pending close. Controls ineffective. Going concern looms large.
AACI
Armada Acquisition Corp. II
10.29-0.01
AEAE
AltEnergy Acquisition Corp.
12.01+0.00
AFJK
Aimei Health Technology Co., Lt
26.96-3.55
AIMTF
Aimfinity Investment Corp. I
7.07-4.03
ATEK
Athena Technology Acquisition C
9.02+0.00
ATII
Archimedes Tech SPAC Partners I
10.37-0.01
CLUS
-
200.00+0.00
HAIAF
Healthcare AI Acquisition Corp.
12.74+0.00
IVAUF
Investcorp AI Acquisition Corp.
13.99+0.00
LVPA
LVPAI GROUP LTD
1.01+0.00